The mTORC2 signaling network: targets and cross-talks
A Ragupathi, C Kim, E Jacinto - Biochemical Journal, 2024 - portlandpress.com
The mechanistic target of rapamycin, mTOR, controls cell metabolism in response to growth
signals and stress stimuli. The cellular functions of mTOR are mediated by two distinct …
signals and stress stimuli. The cellular functions of mTOR are mediated by two distinct …
Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing
D Sztankovics, I Krencz, D Moldvai, T Dankó, Á Nagy… - Scientific Reports, 2023 - nature.com
Alterations in mTOR signalling molecules, including RICTOR amplification, have been
previously described in many cancers, particularly associated with poor prognosis. In this …
previously described in many cancers, particularly associated with poor prognosis. In this …
IDH1 mutations induce organelle defects via dysregulated phospholipids
Infiltrating gliomas are devastating and incurable tumors. Amongst all gliomas, those
harboring a mutation in isocitrate dehydrogenase 1 mutation (IDH1 mut) acquire a different …
harboring a mutation in isocitrate dehydrogenase 1 mutation (IDH1 mut) acquire a different …
The role of metabolic ecosystem in cancer progression—metabolic plasticity and mTOR hyperactivity in tumor tissues
A Sebestyén, T Dankó, D Sztankovics… - Cancer and Metastasis …, 2021 - Springer
Despite advancements in cancer management, tumor relapse and metastasis are
associated with poor outcomes in many cancers. Over the past decade, oncogene-driven …
associated with poor outcomes in many cancers. Over the past decade, oncogene-driven …
Protein kinase B (PKB/AKT) protects IDH-mutated glioma from ferroptosis via Nrf2
Y Liu, FJ Chou, F Lang, M Zhang, H Song… - Clinical Cancer …, 2023 - AACR
Purpose: Mutations of the isocitrate dehydrogenase (IDH) gene are common genetic
mutations in human malignancies. Increasing evidence indicates that IDH mutations play …
mutations in human malignancies. Increasing evidence indicates that IDH mutations play …
A genome-wide profiling of glioma patients with an IDH1 mutation using the catalogue of somatic mutations in cancer database
AL Pappula, S Rasheed, G Mirzaei, RC Petreaca… - Cancers, 2021 - mdpi.com
Simple Summary Glioma patients that present a somatic mutation in the isocitrate
dehydrogenase 1 (IDH1) gene have a significantly better prognosis and overall survival than …
dehydrogenase 1 (IDH1) gene have a significantly better prognosis and overall survival than …
NRF2 in human neoplasm: Cancer biology and potential therapeutic target
Nuclear factor-erythroid 2-related factor 2 (NRF2) is a master regulator of a series of
cytoprotective genes, which protects cells from stress conditions such as reactive oxygen …
cytoprotective genes, which protects cells from stress conditions such as reactive oxygen …
From laboratory studies to clinical trials: temozolomide use in IDH-mutant gliomas
X Sun, S Turcan - Cells, 2021 - mdpi.com
In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the
treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical …
treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical …
Rac1 promotes the reprogramming of glucose metabolism and the growth of colon cancer cells through upregulating SOX9
Metabolic reprogramming is the survival rule of tumor cells, and tumor cells can meet their
high metabolic requirements by changing the energy metabolism mode. Metabolic …
high metabolic requirements by changing the energy metabolism mode. Metabolic …